{"groups":[{"description":"COURSE 1-allopurinol (ALL) orally (PO) 4x daily (QID) d1-14, cyclophosphamide (CTX) intravenously (IV) d1, daunorubicin IV d1-3, vincristine (VCR) IV d1,8,15 \\& 22, dexamethasone (DEX) PO 2x daily (BID) d1-7 \\& 15-21, asparaginase (APG) subcutaneously (SC) d5,8,11,15,18 \\& 22, and filgrastim (FIL) SC d4-11. Ph+ pts imatinib (IMT) PO d15-28 COURSE 2-methotrexate (MTX) intrathecally (IT) d1, cytarabine IV d1-3, DEX eye drops QID d1-4, cotrimoxazole (CRT) PO BID 3x wkly d1-29 and CTX, APG \\& FIL as course 1. Ph+ pts IMT PO d1-28 COURSE 3-VCR IV d1,15 \\& 29, MTX IV \\& IT d1,15 \\& 19, MTX PO q6 hr d1-2,15-16 \\& 29-30, mercaptopurine (6-MP) PO d1-35, leucovorin (LCV) IV d 2,16 \\& 30, LCV PO q6 hr d3-4 \\& CRT PO BID 3x wkly d1-43. Ph+ pts IMT PO d1-42 COURSE 4-alemtuzumab 10,20 or 30 mg SC 3x wkly q4 wk, acyclovir PO QID q6 mo COURSE 5-course 1 COURSE 6-course 2 COURSE 7-course 3 COURSE 8-6-MP PO, VCR IV d1, DEX PO d1-5, MTX PO d1,8,15 \\& 22 and CRT PO BID 3d wkly. Ph+ pts IMT PO d1-28 q24 mo","id":"FG000","title":"Phase I - Alemtuzumab and Combination Chemotherapy"},{"description":"COURSE 1-allopurinol (ALL) orally (PO) 4x daily (QID) d1-14, cyclophosphamide (CTX) intravenously (IV) d1, daunorubicin IV d1-3, vincristine (VCR) IV d 1,8,15 \\& 22, dexamethasone (DEX) PO 2x daily (BID) d 1-7 \\& 15-21, asparaginase (APG) subcutaneously (SC) d 5,8,11,15,18 \\& 22, and filgrastim (FIL) SC d 4-11. Ph+ pts imatinib (IMT) PO d 15-28 COURSE 2-methotrexate (MTX) intrathecally (IT) d1, cytarabine IV d1-3, DEX eye drops QID d 1-4, cotrimoxazole (CRT) PO BID 3x wkly d1-29 and CTX, APG \\& FIL as course 1. Ph+ pts IMT PO d1-28 COURSE 3-VCR IV d 1,15 \\& 29, MTX IV \\& IT d 1,15 \\& 19, MTX PO q6 hr d 1-2,15-16 \\& 29-30, mercaptopurine (6-MP) PO d1-35, leucovorin (LCV) IV d 2,16 \\& 30, LCV PO q6 hr d 3-4 \\& CRT PO BID 3x wkly d1-43. Ph+ pts IMT PO d1-42 COURSE 4-alemtuzumab 30 mg SC 3x wkly q4 wk, acyclovir PO QID q6 mo COURSE 5-course 1 COURSE 6-course 2 COURSE 7-course 3 COURSE 8-6-MP PO, VCR IV d1, DEX PO d1-5, MTX PO d 1,8,15 \\& 22 and CRT PO BID 3x wkly. Ph+ pts IMT PO d1-28 q24 mo","id":"FG001","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"25"}],"type":"Not Alemtuzumab Eligible"},{"reasons":[{"groupId":"FG000","numSubjects":"76"},{"groupId":"FG001","numSubjects":"90"}],"type":"Early discontinuation during course I-IV"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"181"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"66"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"115"}],"type":"NOT COMPLETED"}],"title":"Registration Through Course 3"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Declined Alemtuzumab"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"15"}],"type":"Early exits"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"66"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"50"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"16"}],"type":"NOT COMPLETED"}],"title":"Course IV: Alemtuzumab"}],"preAssignmentDetails":"Two (2) participants cancelled prior to receiving any treatment and were removed from all analyses.","recruitmentDetails":"From June 2003 to May 2007, a total of 302 participants were recruited."}